OSN New York Retina

Katherine Talcott, MD, discussed other potential therapies and their mechanisms of action being evaluated in clinical trials at the OSN New York 2024 conference.

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy.

Ferhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.

The meeting is set to take place from November 8 to 10, 2024 at the Sheraton Times Square Hotel in New York City.